Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

30.69
+0.18000.59%
Volume:1.91M
Turnover:58.22M
Market Cap:3.58B
PE:-6.58
High:31.09
Open:30.85
Low:30.15
Close:30.51
52wk High:43.15
52wk Low:25.77
Shares:116.65M
Float Shares:110.00M
Volume Ratio:1.06
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.77
PE(LYR):-9.61

Loading ...

Viking Therapeutics rises 32.5%

TIPRANKS
·
Sep 22

Movement Alert|Viking Therapeutics Rises 34.37% in Regular Trading, Obesity Drug Maintains 97% Weight Loss Under Reduced Dosing Frequency

Market Focus
·
Sep 22

Why Is Viking Therapeutics Stock (VKTX) Up 32% Today?

TIPRANKS
·
Sep 22

Viking Therapeutics Stock Surges 35%. It Could Challenge Lilly and Novo's Obesity Empire

Dow Jones
·
Sep 22

Viking Therapeutics Surges Nearly 50% Premarket as Once-Every-Two-Week Dosing Retains 97% of Weight Loss

Stock News
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Dow Jones
·
Sep 22

Viking Therapeutics Says Obesity Drug Showed 'Superior' Results in Study; Shares Jump

MT Newswires Live
·
Sep 22

Viking Therapeutics Reports Strong Obesity Drug Maintenance Data

TIPRANKS
·
Sep 22

Viking Therapeutics Shares Rise 38% Premarket After Experimental Drug Maintains Weight Loss in Study

THOMSON REUTERS
·
Sep 22

Viking Therapeutics' Obesity Drug Shows 22% Weight Loss in Study

Reuters
·
Sep 22

Viking Therapeutics reports ‘positive’ results from maintenance study of VK2735

TIPRANKS
·
Sep 22

Viking Therapeutics Reports Vk2735 Maintenance Trial Keeps up to 97% of Weight Loss with Every-Other-Week Dosing

Reuters
·
Sep 22

Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

THOMSON REUTERS
·
Sep 22

Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo

THOMSON REUTERS
·
Sep 22

Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing

THOMSON REUTERS
·
Sep 22

Viking Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since September 2023

Dow Jones
·
Sep 22

Lilly: Foundayo Has Captured Over 30% Of New Patient Share In The U.S. Oral Weight-Loss Drug Market

Bellwether Stocks Movement
·
Sep 15

AstraZeneca's Breast Cancer Drug Etcamah Hits A Phase 3 Setback, Clouding Billions In Potential Sales

Options & Short Sell
·
Sep 14